Talaparib
Generic Name
Talaparib
Manufacturer
Hypothetical Biopharma Co.
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| talaparib 1 mg capsule | ৳ 1,400.00 | N/A |
Description
Overview of the medicine
Talaparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of certain cancers, primarily those with homologous recombination repair (HRR) gene mutations.
Uses & Indications
Dosage
Adults
The recommended dose is 1 mg orally once daily. Dose adjustments may be required based on adverse reactions.
Elderly
No specific dose adjustment is required for elderly patients based on age alone, but monitor for renal/hepatic impairment.
Renal_impairment
For patients with moderate renal impairment (CrCl 30-59 mL/min), reduce the dose to 0.75 mg once daily. For severe renal impairment (CrCl <30 mL/min), reduce to 0.5 mg once daily. Not recommended for end-stage renal disease.
How to Take
Take talaparib capsules orally once daily, with or without food. Swallow the capsule whole; do not chew, crush, or open. If a dose is vomited, do not take an additional dose.
Mechanism of Action
Talaparib selectively inhibits PARP1 and PARP2, enzymes involved in DNA damage repair. By inhibiting PARP, Talaparib prevents cancer cells from repairing damaged DNA, leading to synthetic lethality in cells with existing DNA repair defects (e.g., BRCA1/2 mutations).
Pharmacokinetics
Onset
Not precisely defined, therapeutic effects observed over weeks of treatment.
Excretion
Excreted primarily via feces (approx. 70-80%) with a minor portion excreted renally (approx. 10-15%).
Half life
Approximately 15-20 hours, allowing for once-daily dosing.
Absorption
Rapidly absorbed after oral administration, peak plasma concentrations typically reached within 1-2 hours.
Metabolism
Primarily metabolized by CYP3A4 and other minor pathways.
Side Effects
Contraindications
- Known hypersensitivity to talaparib or any of its excipients.
- Severe myelosuppression (e.g., bone marrow failure).
- Pregnancy and breastfeeding.
Drug Interactions
P-glycoprotein (P-gp) inhibitors
May increase talaparib absorption; monitor for increased side effects.
Strong CYP3A inducers (e.g., rifampin, phenytoin)
Co-administration with strong CYP3A inducers may decrease talaparib exposure; avoid co-administration or adjust dose.
Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin)
Co-administration with strong CYP3A inhibitors may increase talaparib exposure; dose reduction may be necessary.
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture. Keep out of reach of children.
Overdose
There is no specific antidote for talaparib overdose. In the event of an overdose, discontinue talaparib and institute general supportive measures. Manage complications as they arise.
Pregnancy & Lactation
Talaparib can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose. It is not known whether talaparib is excreted in human milk. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 1 month after the last dose.
Side Effects
Contraindications
- Known hypersensitivity to talaparib or any of its excipients.
- Severe myelosuppression (e.g., bone marrow failure).
- Pregnancy and breastfeeding.
Drug Interactions
P-glycoprotein (P-gp) inhibitors
May increase talaparib absorption; monitor for increased side effects.
Strong CYP3A inducers (e.g., rifampin, phenytoin)
Co-administration with strong CYP3A inducers may decrease talaparib exposure; avoid co-administration or adjust dose.
Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin)
Co-administration with strong CYP3A inhibitors may increase talaparib exposure; dose reduction may be necessary.
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture. Keep out of reach of children.
Overdose
There is no specific antidote for talaparib overdose. In the event of an overdose, discontinue talaparib and institute general supportive measures. Manage complications as they arise.
Pregnancy & Lactation
Talaparib can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose. It is not known whether talaparib is excreted in human milk. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 1 month after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months from the date of manufacture
Availability
Specialty pharmacies, Hospital pharmacies (where available)
Approval Status
Investigational / Under Clinical Review
Patent Status
Patented, proprietary
Clinical Trials
Talaparib is currently being investigated in various clinical trials for different cancer types and indications, exploring its efficacy and safety profile.
Lab Monitoring
- Complete blood counts (CBC) with differential, weekly for the first month, then monthly or as clinically indicated.
- Renal function tests (creatinine, BUN) periodically.
- Liver function tests (ALT, AST, bilirubin) periodically.
Doctor Notes
- Confirm HRR gene mutation status before initiating talaparib.
- Monitor complete blood counts weekly for the first month and then monthly, or as clinically indicated.
- Advise patients on potential myelosuppression and instruct them to report any signs of infection or unusual bleeding/bruising.
- Counsel female patients of reproductive potential on contraception requirements due to embryo-fetal toxicity.
Patient Guidelines
- Take the medicine exactly as prescribed by your doctor.
- Do not stop taking talaparib without consulting your doctor.
- Report any new or worsening side effects to your healthcare provider immediately.
- Use effective contraception during treatment and for several months after the last dose.
- Avoid donating blood or blood products during treatment and for 6 months after the last dose.
Missed Dose Advice
If you miss a dose, take it as soon as you remember on the same day. However, if it is less than 12 hours until your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses to make up for a missed dose.
Driving Precautions
Talaparib may cause fatigue, dizziness, or other symptoms that could impair your ability to drive or operate machinery. Exercise caution and avoid these activities if you experience such effects.
Lifestyle Advice
- Maintain good hydration by drinking plenty of fluids.
- Manage fatigue by resting when needed and engaging in light physical activity if possible.
- Discuss any dietary concerns or supplements with your doctor.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.